Program
sonidegib
Also written as “LDE225”, “Sonidegib Phosphate Capsules” and “LDE225+gemcitabine”.
Its studies are mostly in Medulloblastoma · Carcinoma, Basal Cell · Basal Cell Nevus Syndrome · Breast Neoplasms · Pancreatic Neoplasms, led by 2 companies.
Drug pageSonidegib: every studyAll 40 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 150 open or running | phase 2since Dec 15, 2009 | Apr 9, 2009 | none ahead |
| Jemincareits history only | 10 open or running | phase 4since Mar 12, 2025 | Mar 12, 2025 | none ahead |
Also a collaborator on its studies: Sun Pharmaceutical Industries and Zhejiang Hangyu Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 9, 2009First study: phase 1 study in MedulloblastomaFirst studyNCT00880308 · 103 enrolled · United States, Spain, Switzerland and more
- Dec 15, 2009Phase 2 study in Carcinoma, Basal CellNCT01033019 · 25 enrolled · Australia, Austria
- May 12, 2010Phase 2 study in MedulloblastomaNCT01125800 · 76 enrolled · United States, Australia, Canada and more
- Sep 21, 2010Phase 1 study in MedulloblastomaNCT01208831 · 45 enrolled · Hong Kong, Japan, Taiwan
- Mar 30, 2011Phase 2 study in Carcinoma, Basal CellNCT01327053 · 230 enrolled · United States, Australia, Belgium and more
- May 6, 2011Phase 2 study in Carcinoma, Basal CellNCT01350115 · 10 enrolled · Austria, Belgium, Canada and more
- Oct 14, 2011Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01456676 · 11 enrolled · Canada, France, Germany and more
- Dec 5, 2011Phase 1 study in Pancreatic NeoplasmsNCT01487785 · 18 enrolled · United States, Spain, United Kingdom
- Apr 10, 2012Phase 1 study in Breast NeoplasmsNCT01576666 · 120 enrolled · United States, Australia, Belgium and more
- Oct 11, 2012Phase 2 study in MedulloblastomaNCT01708174 · 22 enrolled · United States, Australia, Brazil and more
- Jan 8, 20132 phase 1 studiesNCT01764776, NCT01769768
- Feb 6, 2013Phase 2 study in Primary MyelofibrosisNCT01787552 · 50 enrolled · Australia, Belgium, Canada and more
- Mar 25, 2013Phase 2 study in Leukemia, Myeloid, AcuteNCT01826214 · 70 enrolled · United States, Australia, Austria and more
- Dec 1, 2013Phase 2 study in Basal Cell Nevus SyndromeNCT02002689 · 10 enrolled · United States
TargetBeta
“Smoothened homolog inhibitor”ChEMBL 37, by rule
Other programs on SMO
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| taladegibrule | Eli Lilly | phase 2 | 11 |
Studies
All 15 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02002689Basal Cell Nevus Syndrome · United States | 2 | Terminated | Mar 2015 | 10 |
| NCT01826214Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 2 | Completed | May 2015 | 70 |
| NCT01787552Primary Myelofibrosis · Australia, Belgium, Canada and more | 2 | Completed | Apr 10, 2018 | 50 |
| NCT01769768Advanced Solid Tumor · United States | 1 | Completed | Aug 2016 | 114 |
| NCT01764776Normal Hepatic Function · United States, Belgium, Bulgaria and more | 1 | Completed | Mar 2015 | 33 |
| NCT01708174Medulloblastoma · United States, Australia, Brazil and more | 2 | Completed | Oct 5, 2016 | 22 |
| NCT01576666Breast Neoplasms · United States, Australia, Belgium and more | 1 | Completed | Apr 2015 | 120 |
| NCT01487785Pancreatic Neoplasms · United States, Spain, United Kingdom | 1 | Completed | Jul 2014 | 18 |
| NCT01456676Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Canada, France, Germany and more | 1 | Completed | Feb 2014 | 11 |
| NCT01350115Carcinoma, Basal Cell · Austria, Belgium, Canada and more | 2 | Completed | Oct 2012 | 10 |
| NCT01327053Carcinoma, Basal Cell · United States, Australia, Belgium and more | 2 | Completed | Jun 28, 2013 | 230 |
| NCT01208831Medulloblastoma · Hong Kong, Japan, Taiwan | 1 | Completed | Oct 2013 | 45 |
| NCT01125800Medulloblastoma · United States, Australia, Canada and more | 2 | Completed | Oct 2014 | 76 |
| NCT01033019Carcinoma, Basal Cell · Australia, Austria | 2 | Terminated | Feb 2011 | 25 |
| NCT00880308Medulloblastoma · United States, Spain, Switzerland and more | 1 | Completed | Jul 2013 | 103 |
How it is read
Names in the registry
- “LDE225”, 12 entries
- “Sonidegib Phosphate Capsules”, 1 entry
- “LDE225+gemcitabine”, 1 entry
- “Nilotinib + LDE225”, 1 entry
- “LDE225 0.75%”, 1 entry
Conditions, from the studies’ own filings
- Medulloblastoma, 4 studies
- Carcinoma, Basal Cell, 3 studies
- Basal Cell Nevus Syndrome, 2 studies
- Breast Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.